Checkpoint inhibitor therapy, directed at programmed cell death 1 (PD-1), PD-1 ligand 1 (PD-L1), or cytotoxic T lymphocyte–associated protein 4 (CTLA-4), has revolutionized cancer immunotherapy. The gene discussed is CD274; the disease is cancer.